Phase II study of the tetrahydropyranyl adriamycin–cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma

References

• Carbone A, Volper R, Gloghini A, et al. Non-Hodgkin's lymphoma in the elderly: I. Pathological features at presentation. Cancer 1990;66:1991–1996.
   PubMed Web of Science ®Google Scholar
• Vose JM, Armitage JO, Weisenburger DD, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988;6:1838–1844.
   PubMed Web of Science ®Google Scholar
• Umezawa H, Takahashi Y, Kinoshita M, et al. Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot (Tokyo) 1979;32:1082–1084.
   PubMed Web of Science ®Google Scholar
• Miller AA, Salewski E. Prospects for pirarubicin. Med Pediatr Oncol 1994;22:261–268.
   PubMedGoogle Scholar
• Takagi T, Oguro M. (2″-R)- 4′-o-Tetrahydropyranyladriamycin, a new anthracyclin derivative; its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol 1987;20:151–154.
   PubMed Web of Science ®Google Scholar
• Tsurumi H, Yamada T, Sawada M, et al. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 2004;130:107–113.
   PubMed Web of Science ®Google Scholar
• Kitamura K, Takaku F. Pirarubicin, a novel derivative of doxorubicin, in THP-COP therapy for non-Hodgkin's lymphoma in the elderly. Am J Clin Oncol 1990;13(Suppl. 1): S15–S19.
   Google Scholar
• Niitsu N, Umeda M. THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non-Hodgkin's lymphoma in elderly patients: a prospective study. Leukemia 1997;11:1817–1820.
   PubMed Web of Science ®Google Scholar
• Mori M, Kitamura K, Masuda M, et al. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma. Int J Hematol 2005;81:246–254.
   PubMed Web of Science ®Google Scholar
• Tsurumi H, Hara T, Goto N, et al. A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol 2007;25:107–114.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346: 235–242.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Shah P. Current trends in large cell lymphoma. Leukemia 2003;17:1948–1960.
   PubMed Web of Science ®Google Scholar
• Hara T, Tsurumi H, Goto N, et al. Phase II study of rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma. J Cancer Res Clin Oncol 2010;136:65–70.
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. pp 109–236.
   Google Scholar
• Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860–1861.
   PubMed Web of Science ®Google Scholar
• Sawada M, Tsurumi H, Yamada T, et al. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 2002;68:354–361.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Simon R. How large should a phase II trial of a new drug be? Cancer Treat Rep 1987;71:1079–1085.
   PubMedGoogle Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life-tables (with discussions). J R Stat Soc (Series B) 1972;34:187–220.
   Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109: 1857–1861.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002–1006.
   PubMed Web of Science ®Google Scholar
• Bertini M, Freilone R, Vitolo U, et al. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen. Leuk Lymphoma 1996;22:483–493.
   PubMed Web of Science ®Google Scholar
• Bertini M, Freilone R, Vitolo U, et al. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol 1994;5:895–900.
   PubMed Web of Science ®Google Scholar
• Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3041–3050.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008;9:435–444.
   PubMed Web of Science ®Google Scholar
• Aoki S, Tsukada N, Nomoto N, et al. Effect of pirarubicin for elderly patients with malignant lymphoma. J Exp Clin Cancer Res 1998;17:465–470.
   PubMed Web of Science ®Google Scholar